RAD51 and breast carcinoma: These results were consolidated by chromatin immunoprecipitation (ChIP) results showing that BRD4-binding to the RAD51 promoter was indeed lost in breast cancer cell lines treated with the BRD4 inhibitor JQ1 and correlated with the loss of RAD51 mRNA expression [73].